Halozyme initiated Overweight at Wells Fargo on partnerships, patent moat [Seeking Alpha]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Seeking Alpha
Halozyme initiated Overweight at Wells Fargo on partnerships, patent moatNov. 28, 2022 1:26 PM ETHalozyme Therapeutics, Inc. (HALO)JNJGMABBy:Dulan LokuwithanaSA News EditorPgiam/iStock via Getty ImagesWells Fargo launched its coverage on Halozyme (NASDAQ:The analysts led by MohitBansal, with a $65 per share target on the stock, noted that Halozyme () is a "profitable, high-growth company with earnings power to grow at 21% CAGR through the end of the decade."Arguing that investors have "overly focused on 2027 IP concerns," the team cites an analysis to suggest that Halozyme (Noting that the company is on track to launch several products from now till the end of the decade, the analysts highlight HALO's growth prospects beyond 2030."HALO will likely remain Big Biopharma's partner of choice post-2027 as well due to its proven track record of safety and established regulatory pathway lowering development risk," the team wrote, citing the multiple myeloma therapy Darzalex.A partnership bet
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Mahesh Krishnan Elected to Halozyme's Board of Directors [Yahoo! Finance]Yahoo! Finance
- Mahesh Krishnan Elected to Halozyme's Board of DirectorsPR Newswire
- Why This 1 Value Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- Halozyme to Report First Quarter 2024 Financial and Operating Results [Yahoo! Finance]Yahoo! Finance
- Halozyme to Report First Quarter 2024 Financial and Operating ResultsPR Newswire
HALO
Earnings
- 2/20/24 - Beat
HALO
Sec Filings
- 4/25/24 - Form 3
- 4/17/24 - Form 4
- 4/17/24 - Form 144
- HALO's page on the SEC website